IBKS No2 SPAC - Asset Resilience Ratio

Latest as of September 2025: 0.29%

IBKS No2 SPAC (204840) has an Asset Resilience Ratio of 0.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of IBKS No2 SPAC for a breakdown of total debt and financial obligations.

Liquid Assets

₩132.57 Million

≈ $89.84K USD Cash + Short-term Investments

Total Assets

₩46.46 Billion

≈ $31.49 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how IBKS No2 SPAC's Asset Resilience Ratio has changed over time. See 204840 net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down IBKS No2 SPAC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IBKS No2 SPAC stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩132.57 Million	0.29%
Total Liquid Assets	₩132.57 Million	0.29%

Asset Resilience Insights

Limited Liquidity: IBKS No2 SPAC maintains only 0.29% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

IBKS No2 SPAC Industry Peers by Asset Resilience Ratio

Compare IBKS No2 SPAC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	Drug Manufacturers - Specialty & Generic	24.59%
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	Drug Manufacturers - Specialty & Generic	0.01%
Beijing Winsunny Pharmaceutical CO.LTD SHG:601089	Drug Manufacturers - Specialty & Generic	10.89%
KPC Pharmaceuticals Inc SHG:600422	Drug Manufacturers - Specialty & Generic	16.37%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%
Cheng Du Sheng Nuo Biotec Co. Ltd. A SHG:688117	Drug Manufacturers - Specialty & Generic	3.51%
Jiangsu Jibeier Pharmaceutical Co Ltd SHG:688566	Drug Manufacturers - Specialty & Generic	5.72%

Annual Asset Resilience Ratio for IBKS No2 SPAC (2015–2024)

The table below shows the annual Asset Resilience Ratio data for IBKS No2 SPAC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	10.03%	₩4.26 Billion ≈ $2.89 Million	₩42.44 Billion ≈ $28.76 Million	-0.34pp
2023-12-31	10.37%	₩4.14 Billion ≈ $2.80 Million	₩39.87 Billion ≈ $27.02 Million	-0.98pp
2022-12-31	11.36%	₩4.64 Billion ≈ $3.14 Million	₩40.85 Billion ≈ $27.69 Million	-8.61pp
2021-12-31	19.97%	₩6.37 Billion ≈ $4.32 Million	₩31.89 Billion ≈ $21.61 Million	-7.19pp
2020-12-31	27.16%	₩9.49 Billion ≈ $6.43 Million	₩34.94 Billion ≈ $23.68 Million	+24.68pp
2019-12-31	2.48%	₩658.41 Million ≈ $446.19K	₩26.55 Billion ≈ $17.99 Million	-3.10pp
2018-12-31	5.58%	₩1.76 Billion ≈ $1.19 Million	₩31.56 Billion ≈ $21.39 Million	-48.92pp
2017-12-31	54.50%	₩8.19 Billion ≈ $5.55 Million	₩15.02 Billion ≈ $10.18 Million	-4.17pp
2016-12-31	58.67%	₩7.25 Billion ≈ $4.91 Million	₩12.35 Billion ≈ $8.37 Million	+51.14pp
2015-12-31	7.53%	₩667.27 Million ≈ $452.20K	₩8.86 Billion ≈ $6.01 Million	--

pp = percentage points

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$52.33 Million

₩77.22 Billion KRW

Market Cap Rank

#21768 Global

#1424 in Korea

Share Price

₩1000.00

Change (1 day)

+1.01%

52-Week Range

₩990.00 - ₩1320.00

All Time High

₩8655.23